Skip to main content
Equibles

BALPHARMA · Bal Pharma Limited · Financials

Use BALPHARMA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BALPHARMA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
90.94 INR +2.84 (+3.22%) At close · Nov 13
Rebalance outlook locked
Market Cap
1.45B INR
Shares
15.92M
Volume · Nov 13 22.29K Avg daily vol (3M) 58.58K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
3.12B +2.8%
FY2026 Revenue FY2018–FY2026
Net Income
62.84M -12.9%
FY2026 Net Income FY2018–FY2026
Operating Cash Flow
308.35M +48.7%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2018
INR 3.5B 3.12B 3.03B 3.39B 3.04B 2.81B 2.51B 1.71B 2.12B
INR 124.49M 110.79M 97.71M 100.71M 91.28M 90.4M 95.21M 76.78M 67.71M
INR 183.54M 168.18M 168.54M 152.58M 121.87M 104.05M 119.74M 124.53M 92.72M
INR 80.79M 59.34M — 90.47M 47.49M 91.82M 41.03M -135.29M 28.83M
INR 1.14M -3.86M -20.99M 16.02M 21.29M 34.78M -6.1M -6.38M 25.07M
INR 79.15M 62.84M 72.15M 73.92M 0 56.08M 47.43M 0 0
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 19.1M in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.